OPRX · OptimizeRx Corp · Financials
5 customers — 47% of revenue (the year ended December 31, 2025)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
One customer — 10% of revenue (fiscal 2025)
“one customer that accounted for approximately 10% of total revenue in fiscal 2025 did not generate revenue during the current period, and future revenue from this customer is uncertain.”
3 customers — 10% of revenue (2025)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
5 customers — 49% of revenue (the year ended December 31, 2024)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
2 customers — 10% of revenue (2024)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $95M – $100M | $98.65M | $109.43M | $92.13M | $71.52M | $62.45M | $61.29M | $43.31M | $24.6M | $21.21M | $12.13M | $7.75M | $7.22M | $6.5M | $4.68M | $1.99M | $1.11M | $71.07K | |
| — | $26.42M | $35.83M | $32.75M | $28.62M | $23.48M | $25.65M | $19.21M | $9.16M | $9M | — | — | — | — | — | — | — | — | |
| — | — | $73.6M | $59.38M | $42.9M | $38.97M | $35.64M | $24.11M | $15.44M | $12.21M | $5.95M | $4.34M | $3.6M | $3.28M | $2.82M | $1.87M | — | — | |
| — | — | 67.25% | 64.45% | 59.98% | 62.4% | 58.14% | 55.65% | 62.77% | 57.56% | 49.09% | 55.99% | 49.84% | 50.46% | 60.23% | 94.2% | — | — | |
| — | — | $0 | $0 | — | — | — | $0 | $1.6M | $0 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $288.3K | $269.45K | $445.91K | — | |
| — | $36.28M | — | — | — | $33.49M | $27.7M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $4.23M | $4.22M | $2.3M | — | — | — | — | — | — | — | — | — | $57.87K | $54.71K | — | — | |
| — | $4.29M | $4.33M | $4.33M | $2.4M | $2.02M | $1.97M | $2.08M | $1.28M | $316.5K | $324.55K | $235.28K | $333.95K | $264.34K | $193.79K | $187.1K | $145.32K | $59.93K | |
| — | — | $61.9M | $73.08M | $69.3M | $51.26M | $35.28M | $26.24M | $19.13M | $12.03M | $8.08M | $5.92M | $4.2M | $4.31M | $3.09M | $2.33M | $2.57M | $1.92M | |
| — | $10.9M | $11.69M | -$13.71M | -$26.4M | -$12.29M | $361.1K | -$2.14M | -$3.69M | $180.13K | -$2.13M | -$1.58M | -$597.41K | -$1.03M | -$267.54K | -$454.92K | -$1.45M | -$1.85M | |
| — | — | 10.69% | -14.88% | -36.91% | -19.68% | 0.59% | -4.93% | -15.02% | 0.85% | -17.56% | -20.4% | -8.27% | -15.78% | -5.72% | -22.87% | -130.81% | -2597.95% | |
| — | $15.18M | $16.02M | -$9.38M | -$24M | -$10.27M | $2.33M | -$59.43K | -$2.41M | $496.63K | -$1.81M | -$1.35M | -$263.46K | -$761.99K | -$73.75K | -$267.82K | -$1.31M | -$1.79M | |
| — | $4.68M | $5.29M | $6.16M | $1.45M | — | — | — | — | — | — | — | $0 | $0 | $0 | $100 | $958.64K | -$106.55K | |
| — | $333K | $353K | $329K | $2.19M | $852.3K | $16.98K | $68.58K | $288.03K | $46.21K | $25.94K | $42.31K | — | — | — | — | $1290 | $2842 | |
| — | -$4.15M | -$4.74M | -$5.68M | $1.24M | $852.3K | $16.98K | -$71.81K | -$346.97K | $46.21K | $25.94K | $42.31K | $2267 | $935 | $246 | — | — | — | |
| — | $6.75M | $6.95M | -$19.39M | -$25.16M | -$11.44M | $378.08K | -$2.21M | -$4.04M | $226.34K | -$2.1M | -$1.54M | -$595.14K | -$1.03M | -$267.29K | — | — | — | |
| — | $2.15M | $1.82M | $725K | -$7.6M | — | — | — | -$897.96K | — | — | — | $0 | $0 | $0 | — | — | — | |
| — | $4.6M | $5.13M | -$20.11M | -$17.57M | -$11.44M | $378.08K | -$2.21M | -$3.14M | $226.34K | -$2.1M | -$1.54M | -$595.14K | -$1.03M | -$267.29K | -$454.55K | -$2.12M | -$2.01M | |
| — | — | 4.69% | -21.83% | -24.56% | -18.32% | 0.62% | -5.1% | -12.78% | 1.07% | -17.35% | -19.86% | -8.24% | -15.77% | -5.71% | -22.85% | -190.8% | -2827.02% | |
| — | — | $5.13M | -$20.11M | -$17.57M | -$11.44M | $378.08K | -$2.21M | -$3.14M | $226.34K | — | — | — | — | — | — | — | — | |
| USD/shares | — | $0.25 | $0.28 | -$1.10 | -$1.03 | -$0.64 | $0.02 | -$0.15 | -$0.23 | $0.02 | -$0.21 | -$0.05 | -$0.02 | -$0.04 | — | — | — | — |
| USD/shares | — | $0.24 | $0.27 | -$1.10 | -$1.03 | -$0.64 | $0.02 | -$0.15 | -$0.23 | $0.02 | -$0.21 | — | — | — | — | — | — | — |
| shares | — | — | 18.56M | 18.29M | 17.12M | 17.78M | 17.23M | 14.83M | 13.39M | 10.83M | 9.82M | 29.71M | 24.56M | 22.38M | 14.39M | 17.21M | — | — |
| shares | — | — | 19M | 18.29M | 17.12M | 17.78M | 17.69M | 14.83M | 13.39M | 11.86M | 9.82M | 29.71M | — | 24.01M | 21.2M | 17.21M | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2023: $28.74M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 21 similar-size Health Information Services companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Life Science Companies | $109,214,000 | $85,469,000 |
| Other Revenue | $215,000 | $6,658,000 |